Guided Therapeutics (GTHP) Common Equity (2010 - 2026)

Guided Therapeutics has disclosed Common Equity across 17 years of filings, most recently posting -$5.8 million for Q2 2026.

• In Q2 2026, Common Equity fell 5.32% year-over-year to -$5.8 million; the TTM figure through Jun 2026 stood at -$5.8 million (down 5.32% YoY), while the FY2025 annual figure was -$6.0 million, down 22.85% from the prior year.
• Common Equity came in at -$5.8 million for Q2 2026 at Guided Therapeutics, down from -$5.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$2.7 million in Q3 2022 to a low of -$6.0 million in Q4 2025.
• Average Common Equity over 5 years is -$4.5 million, with a median of -$4.9 million recorded in 2024.
• Year-over-year, Common Equity soared 65.78% in 2022 and plunged 40.78% in 2024.
• Over 5 years, Common Equity stood at -$2.9 million in 2022, then slumped by 32.02% to -$3.8 million in 2023, then retreated by 28.46% to -$4.9 million in 2024, then decreased by 22.85% to -$6.0 million in 2025, then rose by 4.05% to -$5.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$5.8 million in Q2 2026, -$5.2 million in Q1 2026, and -$6.0 million in Q4 2025.